61
Participants
Start Date
November 4, 2021
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2026
SG301
Phase 1a will use an accelerated titration and 3+3 design with 9 dose cohorts: 0.005 mg/kg, 0.05 mg/kg,0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg and 16 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 3 cohorts.
Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing
Beijing Jishuitan Hostipal, Beijing
The First Affiliated Hospital of China Medical University, Shenyang
Shengjing Hospital Affiliated to China Medical University, Shenyang
Wuxi Central Hospital, Wuxi
The First Affiliated Hospital of Bengbu Medical College, Bengbu
Qilu Hospital of Shandong University, Jinan
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Wuhan University Central South Hospital, Wuhan
Xiangyang Central Hospital, Xiangyang
Henan Cancer Hospital, Zhengzhou
Shenzhen Second People's Hospital, Shenzhen
The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang
Shanxi Norman Bethune Hospital, Taiyuan
Hangzhou Sumgen Biotech Co., Ltd.
INDUSTRY